On June 8, 2022, Christopher Lowe, the Chief Financial Officer, Chief Operating Officer and a member of the Board of Directors (the Board") of the Cortexyme, Inc., resigned from his roles as the Chief Financial Officer and Chief Operating Officer of the Company, effective as of June 10, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | +2.91% | +0.95% | +0.95% |
Apr. 01 | Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 26 | Transcript : Quince Therapeutics, Inc. - Special Call |
1st Jan change | Capi. | |
---|---|---|
+0.95% | 45.81M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- QNCX Stock
- News Quince Therapeutics, Inc.
- Cortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer